Metcela
Yokohama, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Metcela develops autologous cardiac stem cell therapies for pediatric heart failure and rare diseases, starting with congenital single ventricle conditions.
CardiovascularRare DiseasesPediatrics
Technology Platform
Autologous cell therapy platform utilizing a patient's own cardiac stem cells (CSCs), which are somatic stem cells with natural compatibility for cardiac tissue repair.
Opportunities
Success with JRM-001 could lead to the first approved regenerative therapy for congenital heart disease in Japan and provide a platform to expand into broader pediatric and adult heart failure indications.
Risk Factors
High clinical and regulatory risk concentrated on a single asset (JRM-001), challenges of autologous cell therapy manufacturing and logistics, and dependence on future financing.
Competitive Landscape
Operates in a niche with few direct competitors for pediatric congenital heart failure cell therapy. Differentiation lies in the autologous CSC approach, strong academic pedigree, and Japanese regulatory designations (Sakigake, Orphan).